CytomX Therapeutics, Inc.
CTMX
$0.9605
-$0.0059-0.61%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 43.17% | 26.71% | 1.58% | 76.45% | 32.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 43.17% | 26.71% | 1.58% | 76.45% | 32.22% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 43.17% | 26.71% | 1.58% | 76.45% | 32.22% |
| SG&A Expenses | -28.15% | 16.73% | 13.43% | -2.80% | 2.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.98% | 26.05% | 19.57% | 2.24% | 22.96% |
| Operating Income | 3,017.33% | 31.64% | -152.45% | 306.21% | 69.82% |
| Income Before Tax | 893.60% | -0.31% | -496.41% | 518.00% | 121.72% |
| Income Tax Expenses | -94.20% | -97.84% | -- | -- | -- |
| Earnings from Continuing Operations | 2,155.20% | 91.71% | -501.10% | 516.52% | 109.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2,155.20% | 91.71% | -501.10% | 516.52% | 109.54% |
| EBIT | 3,017.33% | 31.64% | -152.45% | 306.21% | 69.82% |
| EBITDA | 15,176.67% | 25.87% | -191.93% | 339.70% | 91.43% |
| EPS Basic | 2,036.89% | 81.67% | -372.39% | 436.20% | 107.76% |
| Normalized Basic EPS | 845.21% | -5.33% | -367.65% | 437.82% | 220.66% |
| EPS Diluted | 2,520.24% | 81.67% | -300.00% | 436.20% | 106.33% |
| Normalized Diluted EPS | 845.21% | -5.35% | -367.65% | 435.58% | 220.66% |
| Average Basic Shares Outstanding | 5.13% | 5.40% | 27.57% | 23.82% | 23.37% |
| Average Diluted Shares Outstanding | 5.13% | 5.20% | 27.57% | 24.73% | 23.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |